Shares of Jazz Pharmaceuticals (JAZZ) have gained 8.9% over the past four weeks to close the last trading session at $127.74, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $175.83 indicates a potential upside of 37.7%.The average comprises 18 short-term price targets ranging from a low of $113 to a high of $230, with a standard deviation of $33.34. While the lowest estimate in ...